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INTRODUCTION
Half a year ago, Chinese scientist He Jiankui pushed an ethical boundary by claiming to have treated 
two female infants for potential future HIV infection by altering a small piece of their genome. He 
was thereafter listed among Nature’s 10 people who mattered in 2018. “He was widely criticized for 
ignoring important ethical considerations and exposing the girls to unknown risks for an uncertain 
benefit”, as reported by Nature (Vol. 564, page 329).
The gene editing target that He Jiankui chose was from a study with participants of European 
ancestry, wherein in a cohort of HIV-1-infected individuals, none was found to be homozygote for 
the CCR5Δ32 deletion, despite its relatively high allele frequency (9.2%) in the European population 
(Samson et al., 1996). Later studies further showed that stem cell transplantation from CCR5Δ32 
homozygotes can treat HIV-1-infected individuals (Hütter et al., 2009; Gupta et al., 2019). Thus, 
introducing the deletion of the CCR5 gene seems to be protective against HIV-1 infection. However, 
the potential side effects of the deletion are far from clear.
He Jiankui was criticized for putting the young girls into unknown risks. Cyranoski (2018) timely 
pointed out in Nature News that the target variant was reported to have negative effects on a range 
of human traits. Later, Lander et al. (2019) commented in the same journal to highlight and discuss 
the medical, scientific, and ethical considerations of gene editing in humans, where they pointed out 
that the long-term effects on genetically correlated traits need to be understood before performing 
gene editing on humans.
According to literature, except for documented side effects on, e.g., West Nile virus infection 
(Glass et al., 2006), celiac disease, and autoimmune thyroid disorders in patients with type 1 
diabetes (Słomiński et al., 2017), CCR5 loss of function was actually reported to be favorable for 
multiple sclerosis (Barcellos et al., 2000; Kantor et al., 2003), spontaneous hepatitis C viral clearance 
(Goulding et al., 2005), and chronic and aggressive periodontitis (Cavalla et al., 2018). Although 
CCR5 is clearly involved in the human immune system, it is hard to assess its potential side effects.
Very recently, Wei and Nielsen (2019) reported an assessment of CCR5Δ32 homozygote carriers 
in UK Biobank, who were shown to suffer from 21% increase in their mortality rate. Wei and 
Nielsen predicted that this Δ32 mutation could be highly pleiotropic and potentially increase the 
susceptibility to other common diseases.
Here, from a quantitative genetics perspective, we aim to use UK Biobank as a unified source 
of genomic big data to investigate additional evidence of the substantial pleiotropy of disease-
associated DNA variants, starting from the CCR5 gene that He Jiankui tried to edit using CRISPR.
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ANALYSIS
CCR5Δ32 Does More Harm Than Good 
According to UK Biobank
We first focused on the CCR5Δ32 variant that was imputed with 
quality (variant 3:46414943_TACAGTCAGTATCAATTCTG
GAAGAATTTCCAG_T, info score 0.838) in the UK Biobank 
cohort. This deletion variant was also what was aimed for by He 
Jiankui in his gene editing surgery, as the variant was documented 
to prevent the homozygote carriers from HIV infection (Hütter 
et al., 2009). The association analysis results between this 
variant and 131 curated disease phenotypes with at least 1000 
cases was extracted from the UK Biobank round 2 genome-
wide association study (GWAS) results released by Neale’s lab 
(http://www.nealelab.is/uk-biobank/ukbround2announcement; 
Supplementary Table 1).
The GWAS by Neale’s lab was conducted via a simple linear 
regression of each binary disease outcome vector y (length n ) on 
the CCR5Δ32 genotype dosages g, i.e.,
 y g eobs= + +1µ β  
where μ is the phenotypic mean parameter for CCR5 wildtype 
homozygotes, βobs is the allelic substitution effect of the CCR5Δ32 
deletion on the observed scale, and e is the residual vector. 
When conducting the GWAS, covariates including sex, age, age2, 
sex × age, and sex × age2 were fitted to reduce residual variance, 
and the first 20 principal components of the genomic kinship 
matrix were also fitted to remove the confounding effect due to 
population structure. The analysis was performed on 361,194 
quality-controlled individuals, with restriction to samples of 
white British genetic ancestry. The detailed pipeline can be found 
at https://github.com/Nealelab/UK_Biobank_GWAS.
In order to assess the odds ratio estimates of the CCR5Δ32 
deletion, we transformed the estimated genetic effect from 
the observed scale βˆobs  to its logistic scale βˆ . Typically, the 
phenotypic variance explained by the genetic variant is a very 
small fraction, and then βˆobs, the disease prevalence, and the 
variant’s allele frequency together form a set of sufficient statistics 
for βˆ , making such transformation feasible (see Pirinen et al., 
2013, formula 3.2, and an implementation in Supplementary 
Table 1). This provided the odds ratio of CCR5Δ32 for each of 
the 131 disease phenotypes (Supplementary Table 1). Due to 
the lack of recorded HIV infection incidence in UK Biobank, 
we re-analyzed the contingency table in Samson et al. (1996), 
where the effect of natural CCR5Δ32 deletion was first reported, 
to examine the odds ratio on HIV-1 infection in the Caucasian 
population. Estimated from a logistic regression, the odds ratio 
of a CCR5Δ32 substitution is 0.56 (p = 1.03 × 10−4), though 
CCR5Δ32 homozygotes appear to be completely immune to 
macrophage- and dual-tropic HIV-1 strains (Samson et al., 1996).
The observed p value distribution across the diseases 
significantly deviates from what we expect under the null, 
indicating that the variant has effects on a significant subset of 
the diseases (Figure 1A). For instance, the CCR5Δ32 variant 
has significant effects (false discovery rate < 5%) on rheumatoid 
arthritis (RA), Still disease (SD), ischemic heart disease (IHD), 
coronary heart disease (CHD), CHD with no revascularizations 
(CHDNR), spinal stenosis (SS), and bronchitis. Notably, among 
these seven diseases, the effects of the CCR5Δ32 deletion on 
autoimmune (RA and SD) and other (IHD, CHD, CHDNR, SS, 
and bronchitis) diseases have opposite directions.
From the estimated odds ratios, regardless of statistical 
significance, the CCR5Δ32 deletion appears to elevate the risk for 
93 out of the 131 disease phenotypes in UK Biobank, versus the 
other 38 where the deletion appears to be protective against the 
diseases (Supplementary Table 1). This is notably enriched for 
harmful effects (p = 1.55 × 10−6, Wilcoxon signed rank test with 
continuity correction) if assuming the diseases are independent for 
simplicity. As most of these associations could be statistically zero 
according to the current data, in order to more stringently estimate 
the proportion of harmful effects across these diseases, we modeled 
the 131 GWAS Z scores as drawn from a mixture distribution of
pi µ pi pi µ
−
− + + +N N NZ( , ) ( , ) ( , ).Z1 0 1 10
Via a full likelihood estimation and bootstrapping (code 
available at https://github.com/xiashen/ccr5delta32), we estimated 
the proportion of harmful effects ˆ . ( . )pi + −= = ×0 231 1 6 10 7p  , 
null effects ˆ . ( . )pi 0 110 769 2 1 10= = × −p , protective effects 
ˆ . ( . )pi + = =0 000 0 9999p , and the average harmful effect Z score 
ˆ . ( . )µZ p= = × −1 003 4 0 10 3 . This is equivalent to about 30 out of 
the 131 diseases having elevated risk due to the Δ32 mutation, 
while comparatively, the mutation’s protective effect is nearly 
none (Figure 1B).
Established Disease Susceptibility loci 
Tend to be Pleiotropic
It is arguable that the CCR5Δ32 deletion might happen to be a 
special case, showing substantial pleiotropic effects on a wide 
range of phenotypes. How about potential gene editing for other 
diseases? Here, based on established disease-associated variants, 
we try to examine the likelihood that gene editing would result in 
side effects on other phenotypes.
In order to extend the consideration of pleiotropic effects 
to complex diseases in general, we investigated discovered 
susceptibility loci for six severe diseases in human population: 
breast cancer (Michailidou et al., 2017), lung cancer (McKay 
et al., 2017), coronary artery disease (CAD) (Nikpay et al., 2015), 
type 2 diabetes (T2D) (Morris et al., 2012), bipolar disorder 
(BIP) (Stahl et al., 2019), and major depressive disorder (MDD) 
(Howard et al., 2019). Again, in a different manner, we used 
the publicly available UK Biobank GWAS results by Neale’s lab 
(http://www.nealelab.is/uk-biobank). Each SNP was quantified for 
its number of associations across all the phenotypes (p < 5 × 10−4). 
The genome average of this quantity was 5.56 associations per 
SNP for all the variants (median = 5). Even for the variants with 
minor allele frequency larger than 0.3, the average number of 
associations was 5.64 per SNP (median = 5). For every disease 
among the six, the average number of associations of its reported 
susceptibility loci was larger than the genome average (Figure 1C, 
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Supplementary Table 2). The results indicate that pleiotropic 
effects are ubiquitous and even enriched for many established 
loci associated with complex diseases.
DISCUSSION
Starting from the CCR5Δ32 deletion, a site targeted by He Jiankui in 
his gene editing surgery, we investigated the pleiotropic nature of this 
deletion and some other disease-associated variants, using massive 
publicly available GWAS results from the UK Biobank. The results 
highlight that pleiotropy should always be carefully considered 
before gene editing treatment for human complex diseases.
Our results suggest that, in He Jiankui’s CRISPR experiment, 
even if the surgery does produce a deletion effect the same as 
CCR5Δ32, the treated girls would be prone to an elevated risk of 
cardiovascular and other potential diseases. It also seems true that 
the surgery would be more harmful than beneficial, considering 
the number of diseases that it might have effects on. Some of these 
diseases are not only common, but also essential contributors to 
the mortality rate of the current human population (Timmers 
et al., 2019). Although there is criticism about Wei and Nielsen 
(2019)’s pipeline, regardless of the level of statistical significance 
in their analysis, our additional results here do provide evidence 
that the Δ32 mutation’s potential effect on mortality may be 
related to its side effects on other more common diseases.
FIGURE 1 | Pleiotropic nature of disease-associated variants. (A) Quantile–quantile plot of the −log10 p values of the association between the CCR5Δ32 variant 
and different diseases, including 131 GWASed curated disease phenotypes in the UK Biobank and HIV-1 infection from Samson et al. (1996). Diseases with false 
discovery rate < 5% are labeled. Phenotypes for which the CCR5Δ32 deletion elevates/reduces their risks are colored orange/blue, respectively. The sizes of 
the dots are proportional to the magnitudes of the deviations of their odds ratios from one. The red diagonal line represents equality between the x and y axes. 
(B) Distribution of CCR5Δ32 effects on complex diseases. The genetic effects are shown as Z scores, i.e., standardized by their standard errors. The gray histogram 
shows the observed distribution of Z scores across 131 curated disease phenotypes in UK Biobank. The colored densities give the fitted mixture distribution, 
consisting of three Gaussian components, where the estimated proportion of harmful effects is about 23%. (C) Pleiotropy of the established loci for six diseases is 
evaluated by the number of associations per locus in Neale’s lab round 1 UK Biobank GWAS. Each dot represents the average number of associations per locus for 
the corresponding disease, and the whiskers represent standard errors. MAF: minor allele frequency.
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Besides the issue with pleiotropy, gene editing in humans may 
lead to other unwanted consequences. Although the CRISPR-
Cas9 technology has been shown to be a reliable method to 
introduce mutations to the target site, it appears that He Jiankui 
has also ignored the possibility of any off-target effects that might 
be induced in the process (Zhang et al., 2015). Furthermore, 
from an evolutionary perspective, we should be careful before 
introducing any artificial mutation to the human gene pool, even 
if the introduced mutation might have negligible side effects for the 
population. For instance, as it is likely that the introduced mutation 
is in linkage disequilibrium with another functional variant under 
positive selection, due to genetic hitchhiking (Barton, 2000), the 
introduced mutation can gain allele frequency so that its effects on 
the population are revealed. However, we do not suggest a complete 
ban of gene editing treatments. Similar to the development of 
any treatment, what is essential is the trade-off between positive 
and negative effects. One can imagine that a gene editing surgery 
removing a severely impactful monogenic mutation could be 
valuable to certain individuals, given that the side effects are known 
to be none or so small that they do not matter compared to the 
monogenic disease itself. Unfortunately, for most complex diseases, 
the situation does not appear to be as straightforward at all.
Pleiotropy, i.e., a gene or genetic variant having complex 
effects on various phenotypes, is a very common phenomenon. 
It is encouraging to foresee the potential of gene editing in 
humans as treatments for diseases. However, practitioners such 
as He Jiankui had uninformed opinions towards CCR5Δ32’s 
effect against HIV and showed disrespect to the complexity of 
genome biology resulting from billions of years of evolution. 
The data presented here were all publicly available, sufficient to 
prevent anyone from even considering the experiment on living 
human embryos. Unfortunately, all these established resources 
were overlooked. We provided additional evidence to evaluate 
He Jiankui’s actions and to guide considerations in future gene 
editing research, as it undeniably is a field with great potential.
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